期刊
NATURE PROTOCOLS
卷 9, 期 3, 页码 729-740出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/nprot.2014.050
关键词
-
资金
- Hoffmann La Roche-Yissum Collaboration
- Israel Science Foundation (ISF) [269/12]
- ISF-Legacy Heritage Biomedical Science Partnership [1252/12]
The tumorigenicity of human pluripotent stem cells (hPSCs) is widely acknowledged as a major obstacle that withholds their application in regenerative medicine. This protocol describes two efficient and robust ways to chemically eliminate the tumorinitiating hPSCs from monolayer culture. The protocol details how to maintain and differentiate hPSCs, how to apply chemical inhibitors to cultures of hPSCs and their differentiated progeny, and how to assess the purity of the resultant cell cultures using in vitro and in vivo assays. It also describes how to rescue the cytotoxic effect. The elimination and the rescue assay can be completed within 3-5 d, the in vitro assessment requires another day, and the in vivo assessment requires up to 12 additional weeks.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据